Atavistik Bio, a Cambridge, MA-based biotechnology company discovering precision allosteric therapeutics, raised additional $40M in funding.
The round saw participation from The Column Group, Lux Capital, and Nextech Invest.
The company intends to use the funds to advance its lead precision allosteric small molecule therapeutic in oncology into the clinic and to advance its earlier stage pipeline.
Led by CEO Bryan Stuart, Atavistik Bio is focused on finding functional pockets to discover allosteric precision therapeutics to address patient needs. By integrating its propriety screening technology using the body’s natural regulators, with its AI-enabled drug discovery platform, the company is able to identify novel, biologically relevant allosteric sites for protein or RNA targets, and rapidly advance structural insights into small molecule therapeutics design.
Employing this integrated approach, Atavistik Bio has rapidly identified functional binding pockets for the development of small molecule therapeutics across a broad range of target classes, including kinases, enzymes, receptors, transcription factors, as well as protein complexes and RNA, and translated these insights into a robust discovery pipeline. The company’s internal efforts are focused on oncology and rare diseases. It intends to leverage partnerships to extend the reach of its platform to other therapeutic areas, including metabolic and cardiovascular disease, inflammation and immunology disorders, and neurodegenerative diseases.
Atavistik Bio has raised $100m in aggregate since its launch in August 2021.
FinSMEs
22/12/2023